Melbourne, Australia, 31 October 2019: Sienna Cancer Diagnostics Ltd, (ASX:SDX) (“Sienna” or “the Company”), a medical technology company developing and commercialising innovative cancer related tests, lodges its Appendix 4C – Quarterly Cash Flow Report for the quarter ended 30 September 2019.
The Company had three payments from its U.S. distributor due for receipt within the September quarter. The last payment was received one day after the end of the quarter, on 1 October 2019. The payment amount, US$31,500, will therefore be reported in the Appendix 4C for the December 2019 quarter.
For further information please download the attached PDF:
Download this document
